Annals of Oncology 12:S15-S19, 2001
© 2001 European Society for Medical Oncology
Symposium Article |
Survival, quality of life and breast cancer
1 Istituto di Ricerche Farmacologiche Mario Negri Milan
2 Policlinico Monteluce Perugia
3 Università Federico II Naples
4 Ospedale Pierantoni Forli, Italy
Correspondence to Dr P. Mosconi Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri Via Eritrea, 62 20157 Milan Italy E-mail: mosconi{at}irfmn.mnegri.it
In recent years, evaluating quality of life (QoL) has become increasingly important as an additional measured outcome in cancer clinical trials, in particular in the field of breast cancer. This paper, after a general introduction to the present debate on the methodological issues involved in QoL evaluation, reviews results and open questions regarding the use of this measure in surgical, adjuvant and metastatic studies.
adjuvant treatment, breast cancer, metastatic disease, quality of life, surgical treatment
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Largillier, J.-M. Ferrero, J. Doyen, J. Barriere, M. Namer, V. Mari, A. Courdi, J. M. Hannoun-Levi, F. Ettore, I. Birtwisle-Peyrottes, et al. Prognostic factors in 1038 women with metastatic breast cancer Ann. Onc., December 1, 2008; 19(12): 2012 - 2019. [Abstract] [Full Text] [PDF] |
||||
